ArticleMolecular and clinical oncology2020

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer.

Helena Fohlin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.